Related Experiment Video
Updated: Jul 12, 2025

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
PrP meets alpha-synuclein: Molecular mechanisms and implications for disease
Tuane C R G Vieira1, Caroline A Barros1, Renato Domingues2
1Institute of Medical Biochemistry Leopoldo de Meis and National Institute of Science and Technology for Structural Biology and Bioimaging, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Prion protein (PrP) interactions with alpha-synuclein (aSyn) are crucial for synucleinopathies like Parkinson's disease. Cellular PrP (PrPC) may act as a receptor, mediating aSyn spread and offering potential therapeutic targets.
Area of Science:
- Neuroscience
- Molecular Biology
- Protein Chemistry
Background:
- Prion protein (PrP) discovery revolutionized understanding of protein-misfolding diseases.
- Alpha-synuclein (aSyn) misfolding and aggregation drive Parkinson's disease and synucleinopathies.
- Cell-to-cell spread of aSyn pathology is a key disease mechanism.
Purpose of the Study:
- To provide a comprehensive overview of the interaction between aSyn and cellular PrP (PrPC).
- To discuss the role of this interaction in synucleinopathies.
- To identify knowledge gaps and potential therapeutic avenues.
Main Methods:
- Review of existing literature on PrP and aSyn structure, function, and aggregation.
- Analysis of studies investigating PrPC as a receptor for protein aggregates.
- Synthesis of current understanding of aSyn-PrPC interactions.
Main Results:
- PrPC may function as a receptor or sensor for aSyn aggregates.
- This interaction is implicated in the cell-to-cell transmission of aSyn pathology.
- PrPC's role is observed across various neurodegenerative disorders.
Conclusions:
- The interaction between aSyn and PrPC is a critical factor in synucleinopathy progression.
- Understanding this interplay may reveal novel therapeutic strategies for Parkinson's disease and related disorders.
- Further research is needed to fully elucidate the mechanisms and therapeutic potential.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Neural Regulation
Parkinson's Disease: Overview

